Improvement in dermatomyositis-associated muscle disease with anifrolumab
Leila H. Shayegan(Brigham and Women's Hospital), Ruth Ann Vleugels(Brigham and Women's Hospital), Ellen Anshelevich(Brigham and Women's Hospital), Rochelle Castillo(Brigham and Women's Hospital), Avery LaChance(Brigham and Women's Hospital), Neda Shahriari(Brigham and Women's Hospital), Lorena Acevedo(Brigham and Women's Hospital), Ged G. Wieschhoff(Brigham and Women's Hospital), Nnenna Ezeh(Massachusetts General Hospital), Fatma Dedeoğlu(Boston Children's Hospital), Katharina Shaw(University of Pennsylvania), Yoo Jung Kim(Brigham and Women's Hospital), Allen W. Ho(Brigham and Women's Hospital)
Cited by 12
Related Papers
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems
|Science Immunology|2023|93
Reflectance confocal microscopy
|Journal of the American Academy of Dermatology|2020|76
Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis
|JCI Insight|2020|71
Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus
|JAMA Dermatology|2023|51
Reflectance confocal microscopy
|Journal of the American Academy of Dermatology|2020|47